Kahr Medical

An Israeli biotech is looking to make its name in the jam-packed CD47 space. Is bifunctionality the answer?
Endpoints
Wed, 06/16/21 - 11:46 am
Kahr Medical
autoimmune disorders
fusion proteins
Israel
Kahr raises $18M to test CD47 drug with Roche's Tecentriq
Fierce Biotech
Tue, 02/25/20 - 10:24 am
Kahr Medical
anti-CD47
Roche
Tecentriq